PH 284
Alternative Names: PH-284Latest Information Update: 20 Jul 2023
At a glance
- Originator Pherin Pharmaceuticals
- Class Appetite stimulants
- Mechanism of Action Chemoreceptor cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cachexia
- Discontinued Anorexia
Most Recent Events
- 20 Jul 2023 Discontinued - Preclinical for Anorexia in USA (Intranasal), prior to July 2023 (VistaGen Therapeutics pipeline, July 2023)
- 17 Jul 2023 PH 284 is still in phase II trials for Cachexia in Mexico (Intranasal) (VistaGen Therapeutics pipeline, July 2023)
- 17 Jul 2023 VistaGen Therapeutics plans a clinical trial for Cachexia in USA (Intranasal) , (VistaGen Therapeutics pipeline, July 2023)